Format

Send to

Choose Destination
Can J Hosp Pharm. 2017 Sep-Oct;70(5):358-367. Epub 2017 Oct 31.

Program to Manage New and Expensive Drugs in Pediatrics: Profile of a New Drug Policy and a 12-Month Descriptive Study.

Author information

1
, DPharm, is with the Pharmacy Practice Research Unit, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec.
2
, BPharm, MSc, is with the Pharmacy Department and the Pharmacy Practice Research Unit, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec.
3
, MD, is with the Pediatrics Department, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec.
4
, BPharm, MSc, MBA, FCSHP, FOPQ, is with the Pharmacy Department and the Pharmacy Practice Research Unit, Centre hospitalier universitaire Sainte-Justine, and the Faculty of Pharmacy, Université de Montréal, Montréal, Quebec.

Abstract

in English, French

Background:

With growing financial pressure and the range of new and expensive drugs, hospital administrators, clinicians, and pharmacy directors are facing tough decisions on how to manage drug budgets. At a Canadian mother-child hospital, a policy for new and expensive drugs was developed, with the goal of managing their use and costs.

Objectives:

To describe the development and implementation of a policy for new and expensive drugs in a mother-child teaching hospital and to describe the profile of requests for these therapies over a 12-month period.

Methods:

A brainstorming session was conducted with members of the pharmacy and therapeutics committee to define the criteria for new and expensive drugs at the study hospital and a new process to evaluate requests for these drugs. Over the 12-month period following implementation of the policy, all requests for new and expensive drugs were evaluated through collection and analysis of relevant data.

Results:

The new drug policy was launched on October 1, 2014. Over the following 12-month period, a total of 58 requests for new and expensive drugs were discussed, but only 47 request forms were completed and signed by a physician and a clinical pharmacist.

Conclusions:

New and expensive drugs represent a challenge for clinicians and hospital stakeholders. This study illustrates the implementation of a new policy for these drugs in a mother-child teaching hospital over a 12-month period.

KEYWORDS:

drug policy; emerging drugs; emploi non conforme; management program; médicaments émergents; off-label use; pediatrics; politique sur les médicaments; programme de gestion; pédiatrie

PMID:
29109579
PMCID:
PMC5659247

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center